The discovery and development of vandetanib for the treatment of thyroid cancer

Expert Opinion on Drug Discovery

Volumn 9, Issue 1, 2014, Pages 105-114

  Sim, Michael W ^a   Cohen, Mark Steven ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Familial medullary thyroid cancer; Medullary thyroid cancer; MEN2A; MEN2B; Thyroid cancer; Thyroid cancer treatment; Tyrosine kinase inhibitor; Vandetanib

Indexed keywords

PROTEIN RET; VANDETANIB;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISTANT METASTASIS; DRUG RESISTANCE; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSFECTION; HUMAN; METASTASIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; THYROID MEDULLARY CARCINOMA;

DISEASE-FREE SURVIVAL; DRUG DISCOVERY; HUMANS; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84890451764     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.866942     Document Type: Review

References (55)

1. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-42
2. Quayle FJ, Moley JF. Medullary thyroid carcinoma: Management of lymph node metastases. Curr Treat Options Oncol 2005;6:347-54
3. Campbell MJ, Seib CD, Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer. Curr Opin Oncol 2013;25:39-43. Provides an excellent and concise review of vandetanib.
4. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363(6428):458-60. One of the two landmark studies that showed the role of RET mutation in MEN syndrome.
5. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2(7):851-6. One of the two landmark studies that showed the role of RET mutation in MEN syndrome.
6. Cohen MS, Phay JE, Albinson C, et al. Gastrointestinal manifestations of multiple endocrine neoplasia type Ann Surg 2002;235(5):648-54; discussion 654-5
7. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42
8. Scollo C, Baudin E, Travagli JP. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070-5
9. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association Task Force. Thyroid 2009;19:565-612
10. Abraham DT, Low TH, Messina M. Medullary thyroid carcinoma: Longterm outcomes of surgical treatment. Ann Surg Oncol 2011;18:219-25
11. Orlandi F, Caraci P, Mussa A, et al. Treatment of medullary thyroid carcinoma: An update. Endocr Relat Cancer 2001;8:135-47
12. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002;132(6):960-6; discussion 966-7
13. Parthasarathy R, Cote GJ, Gagel RF. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 1999;59(16):3911-14
14. Drosten M, Hilken G, Bockmann M, et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004;96(16):1231-9
15. Frampton JE. Vandetanib in medullary thyroid cancer. Drugs 2012;72(10):1423-36
16. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:16-4645-55
17. Suzuki M, Makinoshima H, Matsumoto S, et al. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci 2013;104(7):896-903
18. Brave SR, Odedra R, James NH, et al. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int J Oncol 2011;39(1):271-8
19. Guérin O, Etienne-Grimaldi MC, Monteverde M, et al. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol 2012; Epub ahead of print
20. Wu W, Isobe T, Itasaka S, et al. ZD6474, a small molecule targetting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an rthotopic model of non-small cell lung cancer. Proc Am Assoc Cancer Res 2004;45:1051
21. McCarty MF, Whey J, Stoeltzing O, et al. ZD6474, a dual tyrosine kinase inhibitor with activity against VEGF-R and EGF-R, inhibits orthotopic growth and angiogenesis of gastric cancer. Clin Cancer Res 2003;9(Pt 2):6140s
22. Bruns CJ, Kohl G, Guba M, et al. Anti-angiogenic and antitumour activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumour model. Proc Am Soc Cancer Res (2nd ed) 2003;44:604
23. Drevs J, Konerding MA, Wolloscheck T, et al. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004;7(4):347-54
24. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004;64:9101-4
25. Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (''Iressa'')-sensitive and resistant xenograft models. Cancer Sci 2004;95(12):984-9
26. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 2013;49:707-10
27. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90
28. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:36-6056-63
29. Broutin S, Dupuy C, Caillou B, et al. In vitro and in vivo activity of vandetanib in a human medullary thyroid carcinoma model bearing a RET(C634W) activating mutation(abstract no. 1788). 100th Annual Meeting of the American Association for Cancer Research; 18-22 April 2009; Denver CO, USA
30. Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 2011;18(1):1-11
31. Carlomagno F, Guida T, Anaganti S, et al. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocr Relat Cancer 2009;16:233-41
32. Johanson V, Ahlman H, Bernhardt P, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 2007;14(2):433-44
33. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7
34. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9
35. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72
36. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocr Metab 2010;95:2664-71
37. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41. The pivotal Phase III trial that greatly contributed to vandetanib's approval by the FDA.
38. Center for Drug Evaluation and Research. Application number: 022405Orig1s000. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from: Http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 022405Orig1s000ClinPharmR. pdf
39. European Medicines Agency. Assessment report. Caprelsa. Vandetanib. Procedure no. EMEA/H/C/002315//0000 [online]. Available from: Http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/0 02315/WC500123603.pdf
40. Ton GN, Banaszynski ME, Kolesar JM. Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm 2013;70(10):849-55
41. Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab 2011;96:9-2741-9
42. Martin P, Oliver S, Kennedy S-J, et al. Pharmacokinetics of vandetanib: Three phase I studies in healthy subjects. Clin Ther 2012;34:1-221-37
43. Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 2010;49:9-607-18
44. AstraZeneca. Caprelsa 100 mg and 300 mg film-coated tablets: Summary of product characteristics [online]. Available from: Http://www.medicines.org.uk
45. Matin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or intraconazole. Drugs R D 2011;11:1-37-51
46. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and drug administration drug approval summary. Clin Cancer Res 2012;18:3722-30
47. Caprelsa (vandetanib) Food and Drug Administration Risk Evaluation and Mitigation Strategy. 2011. Available from: Http://www.fda. gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/UCM253441.pdf
48. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897-905
49. Hu MI; MD Anderson Cancer Center, AstraZeneca. An international, randomised, double-blind, two-arm study to evaluate the safety and efficacy of vandetanib 150 and 300 mg/day in patients with unresectable locally advanced or metastatic medullary thyroid carcinoma with progressive or symptomatic disease. ClinicalTrials.gov. This study is ongoing, but not recruiting participants. Web. 2013. Available from: www.clinicaltrials. gov/ct2/show/NCT01496313 term=vandetanib+AND+300+AND +150&rank=1
50. Fox E, Widemann BC, Chuk MK. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013;19(15):4239-48
51. Gramza AW; National Cancer Institute. A targeted Ph I/II Trial of ZD6474 (Vandetanib;ZACTIMA) plus the proteasome inhibitor, bortezomib (Velcade (Registered Trademark)), in adults with solid tumors with a focus on hereditary or sporadic, locally advanced or metastatic medullary thyroid Ca (MTC). ClinicalTrials.gov. Web. 2013. Available from: www.clinicaltrials. gov/ct2/show/NCT00923247 term=vandetanib+AND +bortezomib&rank=1
52. Ton GN, Banaszynski ME, Kolesar JM. Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm 2013;70(10):849-55
53. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
54. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
55. Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012;30(15):5508